Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection

See allHide authors and affiliations

Science  08 Jan 2010:
Vol. 327, Issue 5962, pp. 198-201
DOI: 10.1126/science.1178178

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed.  Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Enter the characters shown in the image.

Vertical Tabs

  • Hepatocellular Carcinoma Risk in Chronic Hepatitis C Treatment

    R. E. Lanford and colleagues report that a sustained MicroRNA-122 (miR-122) silencing in the liver of primates with chronic hepatitis C leads to a prolonged and genotype-independent reduction of viremia lasting beyond the treatment period ("Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection," Reports, 8 January 2010, p. 198; published online 3 December 2009). The effectiveness and the sa...

    Show More
    Competing Interests: None declared.